Neoleukin Story

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:4em;'>NT</div>
NLTX -- USA Stock  

USD 13.00  0.60  4.41%

As many of us are excited about healthcare space, it is fair to break down Neoleukin Therapeutics within current market trends. As expected, Neoleukin Therapeutics is starting to reaffirm its true potential as investors are becoming more and more confident in the future outlook. The returns on the market and returns on Neoleukin Therapeutics appear slightly correlated for the last few months. The appearance of strong technical and fundamental indicators of the company suggests a short-term price swing for investors of Neoleukin. The next fiscal quarter end is expected on the 31st of December 2020. The stock experiences an active upward rally.
Published over three weeks ago
View all stories for Neoleukin Therapeutics | View All Stories
Should you trade Neoleukin Therapeutics (NASDAQ:NLTX) based on current technical indicators?
Neoleukin Therapeutics's average rating is Strong Buy from 7 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Neoleukin Therapeutics market sentiment investors' perception of the future value of Neoleukin. Let us look at a few aspects of Neoleukin technical analysis.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Neoleukin Therapeutics. In general, we focus on analyzing Neoleukin Therapeutics stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Neoleukin Therapeutics's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Neoleukin Therapeutics's intrinsic value. In addition to deriving basic predictive indicators for Neoleukin Therapeutics, we also check how macroeconomic factors affect Neoleukin Therapeutics price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Neoleukin Therapeutics' stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Neoleukin Therapeutics in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Neoleukin Therapeutics. Your research has to be compared to or analyzed against Neoleukin Therapeutics' peers to derive any actionable benefits. When done correctly, Neoleukin Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Neoleukin Therapeutics.

How does Neoleukin Stands against Peers?

Analyzing Neoleukin Therapeutics competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Neoleukin Therapeutics across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be.
Check out Neoleukin Therapeutics Competition Details

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions. It is good to see analyst projects for Neoleukin Therapeutics, but it might be worth checking our own buy vs. sell analysis

Purchase by Baker Bros Advisors Lp of 518555 shares of Neoleukin Therapeutics

Legal trades by Neoleukin Therapeutics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Neoleukin insider trading alert for perchase of pre-funded warrants by Baker Bros Advisors Lp, the corporate stakeholder, on 23rd of December 2020. This event was filed by Neoleukin Therapeutics In with SEC on 2020-12-23. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Closer look at Neoleukin Therapeutics Semi Variance

Neoleukin Therapeutics has current Semi Variance of 14.74. Semi-variance provides a good measure of downside volatility for equity or a portfolio. It is similar to variance, but it only looks at periods where the returns are less than the target or average level.

Semi-variance is the square of semi-deviation. Semi-variance is calculated by averaging the deviations of returns that have a result that is less than the mean.

Semi Variance 
 = 
SUM(RET DEV)2 
N(ZERO) 
 = 
14.74
SUM = Summation notation
RET DEV = Actual return deviation over selected period
N(ZERO) = Number of points with returns less than zero
Let's now compare Neoleukin Therapeutics Semi Variance to its closest peers:
NLTX
CURLF
EGRX
EOLS
ENDP
NLTX14.741575656688127
CURLF4.32
EGRX3.16
EOLS25.1
ENDP10.62

Can Neoleukin Therapeutics build up on the current rise?

Current expected short fall is at -3.73. Neoleukin Therapeutics shows above-average downside volatility for the selected time horizon. We advise investors to inspect Neoleukin Therapeutics further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Neoleukin Therapeutics future alpha.

Our Conclusion on Neoleukin Therapeutics

While few other entities under the drug manufacturers?specialty & generic industry are still a bit expensive, Neoleukin Therapeutics may offer a potential longer-term growth to investors. In closing, as of the 27th of December 2020, our analysis shows that Neoleukin Therapeutics follows the market closely. The company is undervalued and projects below average probability of distress for the next 2 years. Our primary 30 days buy-or-sell advice on the company is Hold.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Neoleukin Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com